## Copyright 2024 Chen EYT. All Rights Reserved.
## A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment

References:
1. Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet. 2010 Oct;376(9747):1164–74. 
2. Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. Med Decis Making. 2017 May;37(4):340–52.
3. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208–15.
4. University of California Berkeley and Max Planck Institute for Demographic Research. The Human Mortality Database [Internet]. Available from: https://www.mortality.org.


